Upstream Bio (UPB) Competitors $16.75 +0.47 (+2.89%) Closing price 09/24/2025 04:00 PM EasternExtended Trading$16.86 +0.11 (+0.69%) As of 09/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock UPB vs. MIRM, ADMA, MTSR, PTGX, ZLAB, AAPG, KYMR, LNTH, MLTX, and AKROShould you be buying Upstream Bio stock or one of its competitors? The main competitors of Upstream Bio include Mirum Pharmaceuticals (MIRM), ADMA Biologics (ADMA), Metsera (MTSR), Protagonist Therapeutics (PTGX), Zai Lab (ZLAB), Ascentage Pharma Group International (AAPG), Kymera Therapeutics (KYMR), Lantheus (LNTH), MoonLake Immunotherapeutics (MLTX), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Upstream Bio vs. Its Competitors Mirum Pharmaceuticals ADMA Biologics Metsera Protagonist Therapeutics Zai Lab Ascentage Pharma Group International Kymera Therapeutics Lantheus MoonLake Immunotherapeutics Akero Therapeutics Upstream Bio (NASDAQ:UPB) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership. Which has preferable valuation & earnings, UPB or MIRM? Upstream Bio has higher earnings, but lower revenue than Mirum Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream Bio$2.37M381.01-$62.81MN/AN/AMirum Pharmaceuticals$429.16M8.69-$87.94M-$1.21-61.37 Is UPB or MIRM more profitable? Mirum Pharmaceuticals has a net margin of -13.65% compared to Upstream Bio's net margin of -3,836.58%. Mirum Pharmaceuticals' return on equity of -24.76% beat Upstream Bio's return on equity.Company Net Margins Return on Equity Return on Assets Upstream Bio-3,836.58% -35.90% -26.26% Mirum Pharmaceuticals -13.65%-24.76%-8.50% Do analysts recommend UPB or MIRM? Upstream Bio currently has a consensus target price of $56.50, suggesting a potential upside of 237.31%. Mirum Pharmaceuticals has a consensus target price of $76.50, suggesting a potential upside of 3.02%. Given Upstream Bio's higher probable upside, equities analysts clearly believe Upstream Bio is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Does the media refer more to UPB or MIRM? In the previous week, Mirum Pharmaceuticals had 10 more articles in the media than Upstream Bio. MarketBeat recorded 12 mentions for Mirum Pharmaceuticals and 2 mentions for Upstream Bio. Mirum Pharmaceuticals' average media sentiment score of 0.83 beat Upstream Bio's score of 0.34 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMirum Pharmaceuticals beats Upstream Bio on 9 of the 12 factors compared between the two stocks. Get Upstream Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPB vs. The Competition Export to ExcelMetricUpstream BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$877.65M$3.15B$5.77B$10.41BDividend YieldN/A2.36%5.68%4.62%P/E RatioN/A20.7676.0626.43Price / Sales381.01393.08520.37168.08Price / CashN/A45.9137.5661.52Price / Book1.919.8312.766.39Net Income-$62.81M-$52.73M$3.29B$271.13M7 Day Performance-3.01%1.84%0.77%0.93%1 Month Performance0.12%7.48%4.90%7.52%1 Year PerformanceN/A19.92%66.58%30.06% Upstream Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPBUpstream Bio1.4716 of 5 stars$16.75+2.9%$56.50+237.3%N/A$877.65M$2.37M0.0038MIRMMirum Pharmaceuticals3.4329 of 5 stars$74.22+0.0%$74.44+0.3%+90.5%$3.73B$429.16M-61.41140Analyst ForecastADMAADMA Biologics3.2954 of 5 stars$15.34+0.3%$27.67+80.3%-18.8%$3.67B$426.45M17.90530Positive NewsMTSRMetseraN/A$34.88+2.0%$63.50+82.1%N/A$3.66BN/A0.0081Analyst DowngradePTGXProtagonist Therapeutics1.6307 of 5 stars$58.80+0.7%$67.73+15.2%+41.6%$3.65B$209.18M83.80120Insider TradeZLABZai Lab3.0985 of 5 stars$32.38+1.4%$56.35+74.1%+50.6%$3.63B$398.99M-15.911,869AAPGAscentage Pharma Group InternationalN/A$38.63-4.5%N/AN/A$3.60B$134.35M0.00600Gap DownKYMRKymera Therapeutics1.8782 of 5 stars$49.27+4.2%$59.39+20.5%+0.2%$3.53B$44.71M-14.22170Analyst RevisionLNTHLantheus4.5336 of 5 stars$51.46-0.6%$89.67+74.3%-52.4%$3.51B$1.53B13.72700Trending NewsMLTXMoonLake Immunotherapeutics2.4894 of 5 stars$53.24-0.1%$74.43+39.8%-0.6%$3.42BN/A-19.162Positive NewsAKROAkero Therapeutics3.9879 of 5 stars$42.70-0.4%$81.14+90.0%+69.2%$3.41BN/A-21.3430Positive News Related Companies and Tools Related Companies MIRM Alternatives ADMA Alternatives MTSR Alternatives PTGX Alternatives ZLAB Alternatives AAPG Alternatives KYMR Alternatives LNTH Alternatives MLTX Alternatives AKRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPB) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UPB Stock Alerts